Evaluating basic research strategies

A model has been developed to describe the pharmaceutical research and drug innovation process. The model originally served to show the range of results that could arise from research in the field of infectious disease chemotherapy over a sustained period of time. The main goal of the model was to illuminate the risk/reward/time tradeoff faced by management in selecting a particular research strategy. The results obtained with this model were one of several considerations influencing the research strategy decision of CIBA-GEIGY in 1976 to adapt and strengthen its research effort in infectious disease chemotherapy.This model has so far been applied only for the comparative evaluation of infectious disease chemotherapy research strategies. However, there is no conceptual reason why it should be limited to this field of drug research or indeed to pharmaceutical research at all. This type of analysis should be applicable wherever clear, product-oriented research goals can be identified and defined, where some reasonable financial reward can be attached to achieving these goals, and where an assessment—albeit subjective—can be made of the likelihood of achieving these goals.